Drug intelligence / Profile preview

Mesenchymal stromal cell-derived extracellular vesicles (IDOR)

Development stage
Unknown
Lead developer
IDOR
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) are an investigational exosome-based therapy being developed by the D'Or Institute for Research and Education (IDOR). These extracellular vesicles are nano-sized, membrane-bound particles secreted by mesenchymal stromal cells that carry a cargo of bioactive proteins, lipids, and nucleic acids. In the context of acute respiratory distress syndrome (ARDS), MSC-EVs are designed to modulate the pulmonary and systemic inflammatory response, reduce the production of pro-inflammatory cytokines (mitigating the "cytokine storm"), and promote the repair of alveolar epithelial and endothelial barriers. The therapy is administered intravenously and is currently being evaluated in Phase I/II clinical trials for patients with moderate to severe ARDS, including cases associated with SARS-CoV-2 infection.

Other names
MSC-EVsExtracellular Vesicles From Mesenchymal CellsEVs from MSCs
02

Targets

IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Mesenchymal stromal cell-derived extracellular vesicles (IDOR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesenchymal stromal cell-derived extracellular vesicles (IDOR).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call